18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
23:35 , Jul 9, 2018 |  BC Extra  |  Financial News

Abingworth closes BioVentures VII fund at $315M

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell...
17:10 , Jul 21, 2017 |  BioCentury  |  Finance

Clarus shares

After dipping its toes in the water with a hybrid fund split between traditional venture investments and risk-sharing deals, Clarus has raised a fourth fund dedicated to the latter. Clarus IV closed on July 18...
04:22 , Apr 7, 2017 |  BC Week In Review  |  Company News

Avillion, Merck KGaA deal

The companies partnered to develop Merck’s M1095 (ALX-0761) to treat plaque psoriasis. Avillion will be responsible for developing the candidate through Phase III testing and will also finance development through to a regulatory submission. Phase...
00:40 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

Bosulif: Ph III BFORE data

Top-line data from the open-label, international Phase III BFORE trial in 536 patients with chronic phase Ph+ CML showed that first-line treatment with once-daily 400 mg oral Bosulif met the primary endpoint of a greater...
08:00 , Jan 25, 2016 |  BioCentury  |  Finance

Venturing to share

Abingworth has seen enough success with its clinical risk-sharing investments that it opted to raise a fund dedicated solely to finding more. Last week, the firm closed its Abingworth Clinical Co-Development fund at $105 million....
08:00 , Jan 25, 2016 |  BC Week In Review  |  Financial News

Abingworth Management financial update

Avillion and SFJ finance late-stage trials and incur all of the clinical and regulatory costs and risk in exchange for a prenegotiated return once a therapeutic is approved. Abingworth co-founded both companies with Clarus Ventures....
02:09 , Jan 22, 2016 |  BC Extra  |  Financial News

Abingworth closes $105M risk-sharing fund

Abingworth closed a $105 million fund dedicated to risk-sharing investments in late-stage clinical therapeutic programs from biotech and pharma companies. The firm will invest its eleventh fund, Abingworth Clinical Co-Development Fund (ACCF), via co-development companies...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Bosulif bosutinib: Completed Phase III enrollment

Avillion completed enrollment of 536 patients in the open-label, international Phase III BFORE trial comparing 400 mg oral Bosulif once daily vs. 400 mg oral Gleevec imatinib once daily for 5 years. Last year, Avillion...